AbbVie Inc. (ABBV) Long-Term Debt
The long-term debt for AbbVie Inc. (ABBV) is $59.61 Billion with a year-over-year change of -1.21%. Long-term debt includes bonds, term loans, mortgages, and other borrowings with maturities greater than one year. It represents the company's structural leverage.
ABBV Long-Term Debt Chart
Current Long-Term Debt
$59.61B
$59.61 Billion
Year-over-Year Change
-1.21%
vs. $60.34B prior year
Historical Data
16
Years of data available
Annual Long-Term Debt History
| Year | Long-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $59.61B | $-732.00M | -1.21% |
| 2024 | $60.34B | +$8.17B | +15.67% |
| 2023 | $52.17B | $-6.95B | -11.76% |
| 2022 | $59.12B | $-5.05B | -7.86% |
| 2021 | $64.16B | $-13.37B | -17.24% |
| 2020 | $77.53B | +$14.56B | +23.12% |
| 2019 | $62.98B | +$27.97B | +79.92% |
| 2018 | $35.00B | +$4.05B | +13.08% |
| 2017 | $30.95B | $-5.49B | -15.06% |
| 2016 | $36.44B | +$7.20B | +24.62% |
| 2015 | $29.24B | +$18.70B | +177.47% |
| 2014 | $10.54B | $-3.75B | -26.27% |
| 2013 | $14.29B | $-338.00M | -2.31% |
| 2012 | $14.63B | +$14.60B | +45618.75% |
| 2011 | $32.00M | +$32.00M | — |
| 2010 | $0 | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael